Metabolic shifts in residual breast cancer drive tumor recurrence

Kristina M. Havas,1,2 Vladislava Milchevskaya,1 Ksenija Radic,1 Ashna Alladin,1 Eleni Kafkia,1 Marta Garcia,1 Jens Stolte,1 Bernd Klaus,3 Nicole Rotmensz,4 Toby J. Gibson,3 Barbara Burwinkel,5 Andreas Schneeweiss,6 Giancarlo Pruneri,7 Kiran R. Patil,1 Rocio Sotillo,1,4,8 and Martin Jechlinger1,3

1EMBL Monterotondo, Adriano Buzzati-Traverso Campus, Monterotondo, Italy. 2Istituto Firc di Oncologia Molecolare (IFOM) the Italian Foundation for Cancer Research (FIRC) Institute of Molecular Oncology, Milan, Italy. 3EMBL Heidelberg, Heidelberg, Germany. 4Division of Epidemiology and Biostatistics European Institute of Oncology, Milan, Italy. 5Molecular Biology of Breast Cancer, University Women’s Clinic, Heidelberg, Germany. 6Gynecologic Oncology, National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany. 7Department of Pathology, Biobank for Translational Medicine Unit, European Institute of Oncology, Milan and University of Milan, School of Medicine, Milan, Italy. 8Division of Molecular Thoracic Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. 9Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Heidelberg, Germany.

Tumor recurrence is the leading cause of breast cancer–related death. Recurrences are largely driven by cancer cells that survive therapeutic intervention. This poorly understood population is referred to as minimal residual disease. Here, using mouse models that faithfully recapitulate human disease together with organoid cultures, we have demonstrated that residual cells acquire a transcriptionally distinct state from normal epithelium and primary tumors. Gene expression changes and functional characterization revealed altered lipid metabolism and elevated ROS as hallmarks of the cells that survive tumor regression. These residual cells exhibited increased oxidative DNA damage, potentiating the acquisition of somatic mutations during hormonal-induced expansion of the mammary cell population. Inhibition of either cellular fatty acid synthesis or fatty acid transport into mitochondria reduced cellular ROS levels and DNA damage, linking these features to lipid metabolism. Direct perturbation of these hallmarks in vivo, either by scavenging ROS or by halting the cyclic mammary cell population expansion, attenuated tumor recurrence. Finally, these observations were mirrored in transcriptomic and histological signatures of residual cancer cells from neoadjuvant-treated breast cancer patients. These results highlight the potential of lipid metabolism and ROS as therapeutic targets for reducing tumor recurrence in breast cancer patients.

Introduction

Despite advances in detection and therapy, breast cancer remains the second leading cause of cancer-related death in women. Mortality is largely due to tumor recurrence following initial therapeutic intervention (1). Recurrence arises from local and/or disseminated residual cancer cells, which survive treatment and are generally referred to as minimal residual disease (MRD) (2). The concept of MRD as the substrate for tumor recurrence is strongly supported by the negative prognostic value associated with the persistence of disseminated tumor cells in breast cancer patients following neoadjuvant therapies (3). Despite its central role in breast cancer progression, in-depth characterization of this population has been hindered by the difficulty in obtaining clinical samples of MRD.

Due to the elusive nature of MRD in patients, animal models that faithfully recapitulate human disease and permit the study of MRD are the method of choice to understand mechanisms of recurrence (4). Here, we utilize 2 conditional mouse models of recurrent mammary tumorigenesis; TetO-cMYC TetO-Neu MMTV-rtTA (hereafter referred to as MYC/NEU) and TetO-cMYC TetO-KrasG12D MMTV-rtTA (hereafter referred to as MYC/KRAS) (5–7). In both models, tissue-specific induction of oncogene expression results in the rapid onset of invasive mammary carcinomas. These tumors display strong oncogene addiction; hence, following oncogene inactivation, they completely regress to a nonpalpable state (5–7). As in breast cancer patients, these mice develop spontaneous tumor recurrences after complete regression, making them suitable models of MRD (5).

To characterize minimal residual cancer cells, we established organotypic 3-dimensional (3D) cultures of primary mammary epithelial cells (organoids) from our mouse models (8). These models permitted isolation of pure residual cancer cell populations following oncogene inactivation. Transcriptome analysis of residual cells revealed a dormancy signature along with strong alterations in lipid metabolism — features we could verify both in mice and in tissue obtained from human breast cancer patients following successful neoadjuvant therapy. Here, we address the consequence of aberrant lipid metabolism in MRD, demonstrating that altered lipid metabolism coupled with restricted antioxidant capacity drives the accumulation of ROS and DNA adducts, which potentiate tumor recurrence.

Results

Oncogene inactivation results in persistence of a transcriptionally distinct state with defining metabolic signatures. To overcome the covert nature of MRD, we employed organoid cultures of primary
mammary epithelial cells for transcriptional characterization of this rare population (8). Cells were derived from preclinical mouse models of recurrent breast cancer in which the tissue-specific expression of MYC/KRAS or MYC/NEU (NEU is also known as HER2) were regulated by doxycycline (Figure 1A). Briefly, primary mammary epithelial cells were isolated from adult (>8 weeks of age) virgin mice, and a single cell suspension was seeded into Matrigel, where the cells developed into hollow, polarized acinar structures. Doxycycline addition to the media induced transgene expression, resulting in a rapid onset of proliferation and filling of the acini. Following 5 days of induction, the doxycycline was removed from the media. Strong oncogene addiction in these models resulted in a rapid onset of apoptosis upon oncogene silencing by doxycycline removal (Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/JCI89914DS1). The population of cells that survive oncogene withdrawal are referred to as regressed and represent an MRD correlate state. Use of this system allowed us to isolate synchronized cultures that closely mirrored the histological changes and expression kinetics observed in mammary gland biopsies spanning from steady state to tumor induction through to a regressed (MRD correlate) state (Figure 1A and Supplemental Figure 1, A and B; ref. 8).

Figure 1. Identifying temporally deregulated genes in a breast cancer model. (A) Left panel: Mouse models of recurrent mammary tumorigenesis were used for in vivo studies. These studies were complemented by organoid cultures derived from primary mammary epithelial cells isolated from adult (>8 weeks of age), virgin mice. MG, mammary gland. Red circles, mammary tumors; white circles, regressed tissue; black-filled dots, in vitro tumor correlates; hollow dots, in vitro regressed tissue correlates. Right panel: in vitro (right upper panels) and corresponding in vivo (right lower panels) transgene-specific c-Myc staining of acini/mammary glands at the never-induced, 5-day-on, and regressed (5 days in the presence of doxycycline, then 7 days grown in media without doxycycline) timepoints. Scale bar: 50 μm. (B) Principal component analysis of variance-stabilization and normalization–processed (VSN-processed) expression data from never-induced (yellow), 5-day-on doxycycline (red), and regressed (blue) MYC/KRAS and MYC/NEU cultures. (C) Reporter pathways upregulated in gene sets derived from the comparisons of never-induced to tumor correlate (5-day-on) and never-induced to MRD correlate (regressed) in both MYC/KRAS and MYC/NEU cultures. A, MYC/NEU 5-day-on versus never-induced; B, MYC/KRAS 5-day-on versus never-induced; C, MYC/NEU regressed versus never-induced; and D, MYC/KRAS regressed versus never-induced.
Next, we asked if the alterations in cellular metabolism observed in residual cells reflected attributes of the initial tumor metabolism. To tackle this, we performed metabolism-specific pathway enrichment analysis for the differentially expressed genes when comparing the tumor (5-day-on) versus never-induced states, in addition to the regressed versus never-induced states. Significantly enriched metabolic pathways (reporter pathways) were thereby identified as those containing no less than 3 genes in a set and a nonadjusted P value threshold of 0.05. The 5-day-on cultures for both MYC/KRAS and MYC/NEU displayed strong upregulation of multiple pathways, including oxidative phosphorylation, glycolysis, and pentose phosphate pathway, in support of the increased demands for biomass required to sustain growth and proliferation (Figure 1C and Supplemental Table 1). Within the regressed population, we observed persistence of 2 specific pathways found in the tumor state — namely, the oxidative phosphorylation and the pentose phosphate pathways. The analysis also revealed evidence for modulation of lipid catabolic pathways, such as mitochondrial and peroxisomal β-oxidative pathways, suggesting a pronounced alteration in lipid metabolism unique for the regressed state (Figure 1C).

Several Gene Set Enrichment Analysis (GSEA) tools were employed for the initial characterization of the differentially regulated gene sets associated with the regressed state. These analyses indicated that regressed cells were largely a dormant population, due to the underrepresentation of several pathways associated with cell cycle progression. This is in line with our observations of very low Ki-67 positivity in residual acini following regression (Supplemental Figure 1A). On the other hand, the overrepresented gene sets indicated that the regressed cells, while largely dormant, retained a degree of oncogenic memory and appeared to harbor alterations in cellular metabolism (Supplemental Figure 1, C and D).
The observed increase in FA stores suggested that regressed mammary glands were preferentially deriving cellular energy from β-oxidation of FAs. Thus, we determined the flux of 1-14C-labeled palmitate through mitochondrial β-oxidation (16) in mitochondria isolated from mammary glands (Figure 3F). We observed a significant increase in β-oxidative flux of labeled palmitate in mitochondria isolated from the regressed animals for both MYC/KRAS and MYC/NEU models over age-matched controls (Figure 3G). Increased catabolism of FAs via β-oxidative pathways together with the increases in the levels of FASN and other auxiliary pathways of de novo FA synthesis is indicative of a maintenance of a neoplastic lipogenesis phenotype within the population of cells that survive oncogene withdrawal (17).
Figure 4. Elevated levels of oxidative stress following oncogene inactivation. (A) Staining of organoid cultures with oxidative stress indicator DCFDA (green), superoxide specific Mitsox (red), and DAPI (gray). Single channel and merged representative images of never-induced (control), MYC/KRAS and MYC/NEU structures, and MYC/KRAS structures treated with N-acetylcysteine (NAC). Images are representative of triplicate experiments. Scale bar: 14 μm. (B) FACS was performed on regressed and control mice. To control for possible doxycycline effects, mice lacking the reverse tetracycline transactivator were used and placed in experimental cages along with the experimental mice and placed on a diet of chow containing doxycycline. When experimental mice developed a total tumor load of 2 cm³, all animals, experimental and control, were placed back on normal chow. Animals were maintained on doxycycline-free chow for >8 weeks before being sacrificed for analysis. Red circles, mammary tumors; white circles, regressed tissue. (C) DCFDA was added to previously published FACS-based protocols for separation of mammary epithelial subpopulations. Upper panel: Representative FACS separation of subpopulations using previously published combination of CD29/CD24/CD49f for control, and MYC/KRAS and MYC/NEU regressed mice. Lower panel: Representative histograms of DCFDA in mammary epithelial cells isolated from age-matched control and regressed animals for the CD29<sup>hi</sup>/CD24<sup>hi</sup>/CD49f<sup>med</sup> (luminal progenitors), CD29<sup>hi</sup>/CD24<sup>med</sup>/CD49f<sup>med</sup> (myoepithelial), and CD29<sup>hi</sup>/CD24<sup>med</sup>/CD49f<sup>hi</sup> (stem) populations. These results were representative for n = 9 (control), n = 3 (MYC/NEU), and n = 6 (MYC/KRAS) independent experiments. (D) Quantification of fold-change of MFI for DCFDA over age-matched control. Parous animals were included as a control for inflammation-driven oxidative stress. Luminal progenitors: MYC/KRAS vs. control, P = 0.0006; MYC/NEU vs. control, P = 0.002. Myoepithelial: MYC/KRAS vs. control, P = 0.0003; MYC/NEU vs. control, P = 0.03. Stem: MYC/KRAS vs. control, P = 0.0084 enriched populations. One sample t test. Data represented as mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001.
Residual cells and mammary glands following oncogene withdrawal contain elevated levels of ROS. The increased flux of FA oxidation in regressed mammary glands, in combination with steady levels of NOXA enzymes and overall transcriptional downregulation of antioxidant enzymes in these cells (Supplemental Figure 3, A and B), further strengthened the prediction that the regressed state exhibits oxidative stress, which we assessed by employing the indicators 2',7'-dichlorofluorescein diacetate (DCFDA), dihydroethidium (DHE), and MitoSOX. Indeed, we observed higher levels of oxidative stress both in the 5-day-on and regressed organoids derived from both models in comparison with the never-induced controls (Figure 4A and Supplemental Figure 3, C and D). Importantly, scavenging by the addition of 20 μM N-acetylcysteine (NAC) confirmed that the indicators indeed sensed ROS (Figure 4A).

To verify the organoid findings in vivo, we isolated cells directly from both regressed and age-matched control mammary glands and analyzed the level of oxidative stress by FACS. In order to address whether elevated ROS was restricted to a specific subpopulation of the mammary epithelium, we utilized an established FACS protocol for separation of mammary epithelial subpopulations (18, 19) together with DCFDA as the ROS indicator (Figure 4B). Interestingly, significantly elevated levels of ROS were detected in the stem cell, myoepithelial, and progenitor populations isolated from regressed mammary glands, suggesting that the elevated ROS is not limited to any one mammary epithelial compartment (Figure 4, C and D).

MYC has recently been shown to play an important role in the regulation of tumor-associated FA oxidative pathways (20). To assess for a MYC-specific memory effect in the regressed population, we evaluated the levels of oxidative stress in mice whose tumors were driven by NEU alone (TetO-Neu MMtv-rtTA) and confirmed an increased level of oxidative stress in the regressed mammary glands, despite the absence of MYC, suggesting that the increase in ROS we observed is a general effect associated with oncogene inactivation and not necessarily related to the oncogenotype of the primary tumor (Supplemental Figure 3E).

To exclude that the elevated ROS levels were due to inflammation associated with mammary remodeling following oncogene withdrawal, we used parous mice as a control. Utilizing parous mice that had undergone 3 rounds of pregnancy and weanings, we observed no significant elevation of oxidative stress in any of the parous-derived mammary subpopulations (Figure 4C). In addition, analysis of previously published parity-induced transcriptional changes in mammary cells (GSE40877) showed distinct transcriptional profiles in comparison with our dataset (Supplemental Figure 4, A and B; ref. 21), excluding the possibility that mere tissue architecture remodeling would explain changes in lipid metabolism, cell cycle activity, and oxidative stress in the regressed cell population.

In summary, we found clear signs of oxidative stress in the regressed state of both organoids and mammary glands of breast cancer mouse models following oncogene withdrawal.

**Lapatinib treatment results in elevated ROS and lipid storage.**

The preclinical models used in this study theoretically mimic a perfect therapeutic setting, since the expression of the driving oncogenes is both spatially and temporally regulated by the addition or exclusion of doxycycline. Organoid cultures derived from this system have allowed us to model and characterize an MRD correlate state, which displays heightened oxidative stress and increased lipid stores in comparison with never-induced cells. This finding has been confirmed in mammary glands derived from regressed mice. However, these results do not completely reflect the clinical setting where the disease is managed through administration of systemic adjuvant therapies. To address this in the organoid culture, we treated organoids overexpressing MYC/NEU with the NEU tyrosine kinase inhibitor lapatinib.

Similar to the oncogene inactivation setting, treatment with lapatinib resulted in a rapid clearing of the organoids, despite the continuous administration of doxycycline, with persistence of a regressed population. We stained the population of cells surviving the pharmacological treatment for FASN, ROS, and lipid droplet accumulation (Supplemental Figure 5) to correlate them with the oncogene-inactivated structures (Figure 3, C and D, and Figure 4A) and observed an increase in FASN protein levels as seen in immunofluorescence. Additionally, increased lipid stores and ROS were observed in regressed lapatinib-treated structures similar to the oncogene-inactivated counterparts. The lack of lipid droplet accumulation or elevated ROS in the lapatinib-treated never-induced control cells excluded the possibility of off-targets being responsible for the effects seen in the lapatinib-regressed organoids. We conclude that inactivation of the oncogenes, utilizing the described inducible system, results in a regression comparable with that obtained with pharmacologic inhibition.

**Aberrant lipid metabolism drives oxidative DNA damage following oncogene inactivation.** Increased levels of oxidative stress can cause damage to nucleic acids, proteins, and lipids and can also affect cellular signaling (22). Oxidative stress has long been implicated in aging and tumorigenesis, making it a good candidate for driving the dormant population of residual cells toward tumor recurrence. To test if the higher levels of ROS led to oxidative DNA damage, we performed immunofluorescence on mammary glands of regressed and control mice for the presence of FASN together with 8-Oxo-2’-deoxyguanosine (8-OHdG), one of the major products of DNA oxidation. Despite no appreciable increase in global levels of γH2AX, we observed elevated levels of 8-OHdG in regressed mammary glands from both MYC/KRAS and MYC/NEU models compared with controls (Figure 5A and Supplemental Figure 6, A and B). Given the adduct specificity of 8-OHdG, we confirmed the general presence of oxidized DNA utilizing a modified comet assay including formamidopyrimidine DNA-glycosylase. Indeed, we again observed an increase in the percentage of DNA damage in the regressed population (Supplemental Figure 6C), despite an increased initiation of base excision repair (BER; Supplemental Figure 6D).

We have demonstrated that an MRD correlate state is characterized by elevated oxidative stress and DNA adducts. The potential to disrupt proposed drivers, FASN and fatty acid β-oxidation, of these hallmarks provides an attractive therapeutic avenue in the prevention of tumor recurrence. To test this hypothesis in vitro, following oncogene inactivation, 2 small molecules — C75 and etomoxir — were administered to organoid cultures to explore their effects on ROS and adduct formation.

### References

1. TetO-Neu MMtv-rtTA
2. 2',7'-dichlorofluorescein diacetate (DCFDA)
3. dihydroethidium (DHE)
4. MitoSOX
C75 (4-methylene-2-octyl-5-oxotetra-hydrofuran-3-carboxylic acid) is a semisynthetic inhibitor of FASN that functions through binding of the \( \beta \)-ketoacyl synthase subunit. FAs are synthesized by FASN through addition of Acetyl-CoA to Malonyl-CoA via an NADPH-dependent condensation step. This reaction is carried out by the \( \beta \)-ketoacyl synthase subunit of FASN; the binding of C75 results in the obstruction of FA synthesis. Downstream, etomoxir inhibits mitochondrial FA \( \beta \)-oxidation by irreversibly binding carnitine palmitoyltransferase 1 (CPT1) and preventing entry of long-chain FAs into the mitochondria (Figure 5B).

Following 24 hours of treatment, we observed a significant reduction in oxidative stress, as measured by DCFDA in FACs analysis, in the populations of regressed cells treated with either inhibitor; the control groups remained largely unchanged (Figure 5C).

Next, we verified whether the observed reduction of overall oxidative stress could be translated to a reduction in adduct formation in the treated cultures. In order to retain genomic integrity, DNA adducts are usually resolved by the BER pathway. In BER, the excision of an adduct results in the formation of an apurinic/apyrimidinic (AP) site, which can be detected using a biotinylated aldehyde reactive probe (ARP) that reacts with the aldehyde ring of the opened AP sites (Figure 5D; refs. 23, 24). This assay clearly showed a significant increase in ARP incorporation in the regressed samples compared with control (Figure 5E and F). However, following treatment with either C75 or etomoxir, significant reductions in ARP incorporation were observed for DNA isolated from treated regressed cultures (Figure 5E). Taken together, the efficacy of both C75 and etomoxir to decrease overall ROS and AP site incidence in regressed mammary glands is consistent with our proposal that increased FA metabolism drives the acquisition of ROS-driven point mutations. Intriguingly, these results suggest that the inclusion of drugs targeting FA catabolism in adjuvant settings could improve long-term survival rates for breast cancer survivors.

Reducing ROS levels and proliferation of mammary epithelium attenuates recurrence in vitro and in vivo. During the ovarian estrous cycle, the mammary gland undergoes remodeling accompanied by expansion of the stem and luminal progenitor compartments (Figure 6A; ref. 25). We have demonstrated above that regressed mammary glands harbor higher levels of oxidative DNA damage. Oxidative DNA damage is highly mutagenic, with incorrect base insertion during replication being the most common mechanism of ROS-driven mutagenesis. Hormone-driven proliferation of the mammary epithelium, which occurs during every estrous cycle, forces residual cells (elevated in adduct-potentiating ROS) to divide and is, thus, likely to be an important driver for promoting acquisition of somatic mutations and recurrence.

As previously mentioned, the regressed structures are largely dormant, with very low Ki67 positivity (Supplemental Figure 1A). Therefore, to test the effect of targeted ROS therapy (by supplementing NAC) on the onset of recurrence, we recapitulated the hormonal cycle–induced expansion in vitro by serial reseeding of the regressed organoids. To that end, the regressed and never-induced organoids were singularized and reseeded into fresh Matrigel. With each reseeding, a subset of cells divided and formed new organoid structures. These reseeded organoids were cultured in either normal media or in the presence of NAC. Analysis of reseeded organoids indicated that, in comparison with the reseeded never-induced cultures, the regressed reseeded cells displayed a NAC-independent persistence of increased FASN expression and lipid droplet accumulation (Supplemental Figure 7A), suggesting that altered lipid metabolism is a stable phenotypic in this population.

Following an average of 4 reseedings, we detected spontaneous relapses only in organoids derived from reseeded regressed structures that could be propagated as solid-growing in vitro relapses (Figure 6B). Sequencing of independent in vitro relapses revealed newly acquired mutations within the rtTA region that render them independent of doxycycline and lead to reexpression of the oncogene (Supplemental Figure 7B; ref. 5). Moreover, injection of cells from in vitro relapses into the cleared mammary fat pad of \( \text{Rag}^{1-} \) mice resulted in the formation of tumors closely resembling in vivo relapses from the same mice (Supplemental Figure 7C). To test if ROS have a causal role in generating de novo somatic mutations and relapse, we reseeded cells as described above in the presence of the ROS scavenger NAC. This resulted in a near-complete abrogation of in vitro relapses (Figure 6B).

The findings from our ex vivo organoid culture highlighted the importance of proliferation for driving somatic mutation acquisition and tumor recurrence from a residual cell population. These observations prompted us to develop a 2-pronged strategy for attenuating tumor recurrences in vivo, either by scavenging ROS or through elimination of the hormone-driven proliferation of the mammary gland (26, 27). Following a round of oncogene-induced tumorigenesis and full regression to nonpalpable state by oncogene withdrawal, mice were either treated with the ROS scavenger...
Figure 6. Progesterone antagonists and ROS scavengers attenuate tumor recurrence. (A) The nonpregnant adult mammary gland undergoes profound morphological changes during the ovarian estrous cycle. A specific 2-fold expansion of the alveolar branching coincides with the peak in progesterone during diestrus. The hormone-driven induction of proliferation can be recapitulated in vitro through serial reseeding of organoid cultures. Reseeding of singularized cells stimulates de novo proliferation, resulting in the formation of acinar structures, similar to initial acini formation. (B) Generation of in vitro relapses through continuous reseeding of singularized cells. Represented as relapse-free persistence for never-induced, regressed, and regressed + N-acetylcysteine (NAC) (20 μM) populations; n = 6 independent experiments. Lower panel: Representative brightfield images of acinar structures from serially reseeded cultures at the third reseeding for hollow never-induced structures and corresponding regressed structures with first appearance of in vitro relapse. Scale bar: 50 μm. (C) Attenuation of tumor recurrence following treatment with progesterone antagonists and ROS scavengers. Upper panel: Experimental timeline in which MYC/KRAS regressed mice were treated with NAC, mifepristone, or the combination of NAC/mifepristone. Treatment began 2 weeks following oncogene inactivation and continued until spontaneous recurrence or 80 weeks after oncogene inactivation. Lower left panel: Role of mifepristone, a progesterone-receptor modulator that blocks hormone-driven expansion of the mammary gland. We postulated that cessation of proliferation would result in a decrease in somatic mutations generated via replication through oxidative DNA adducts, subsequently lowering the rate of tumor recurrence. The survival curve (lower right) represents relapse-free survival percentages for the 4 cohorts of mice treated with NAC, mifepristone, or the combination of NAC/mifepristone, as well as control nontreated. Significance was calculated using the log-rank (Mantel-Cox) test confronting NAC cohort, P = 0.0342; mifepristone cohort, P = 0.0004; and NAC + mifepristone cohort, P = 0.0039 with untreated. No significant difference was seen noted between the 2 mifepristone containing cohorts P = 0.3995. *P < 0.05, **P < 0.01, ***P < 0.001.

Downloaded from http://www.jci.org on November 3, 2017. https://doi.org/10.1172/JCI89914
NAC, the progesterone antagonist mifepristone, or a combination of mifepristone and NAC. We have employed the use of mifepristone as a progesterone antagonist in our studies to halt the expansion of the mammary alveolar epithelium that coincides with the peak in progesterone during diestrus of the ovarian estrous cycle (Figure 6, A and C; ref. 28). Mifepristone has been successfully used in a similar setting in the prevention of BRCA1-mediated tumorigenesis (27) and is currently under evaluation in a phase 2 clinical trial (NCT01898312) for its effectiveness in eliminating ovarian estrous cycle–driven breast cell proliferation in a preventive setting for patients harboring germline BRCA1/2 mutations. Despite diminished/reduced scavenging toward the end of the weekly treatment schedule (Supplemental Figure 7D), NAC-alone–treated animals had a significant delay in the onset of tumor recurrence (Figure 6C), while relapse onset was nearly abrogated in both the mifepristone and the combined mifepristone and NAC treatment cohorts (Figure 6C and Supplemental Figure 7E). These findings demonstrate, both in vivo and in vitro, that ROS scavenging has a beneficial effect on prevention of tumor relapse and, coupled with prevention of hormone-driven proliferation, may provide a new opportunity for therapeutic intervention to attenuate spontaneous tumor recurrences.

Elevated FA metabolism is a communal hallmark of cells surviving neoadjuvant treatment in human breast cancer patients. Neoadjuvant therapeutic approaches may be delivered to breast cancer patients to induce downstaging, thus rendering a locally advanced tumor operable, but they also provide the advantage of allowing the study of the effect of systemic therapies on tumor survival (29). Transcriptome analysis of tumors before and after successful neoadjuvant therapy should provide the gene expression signature of residual cells (30). To that end, we performed RNA-seq on 7 matched cases of preneoadjuvant treatment core biopsies and posttreatment surgical samples (ArrayExpress database; E-MTAB-4632)(Supplemental Table 3). Furthermore, we reanalyzed the previously published human dataset (GSE32072) and compared both human datasets to our mouse–derived repressed mammary duct organoid datasets for the 5-day-on versus regressed comparison, resembling the neoadjuvant setting.

Focusing on the gene sets that were overrepresented in the treated versus pretreated samples, we employed reactome pathway enrichment analysis to evaluate the degree of overlap of the transcriptional response between the mice and the 2 human datasets (Supplemental Figure 8 and Supplemental Table 4). Considering that datasets were not stratified for intrinsic tumor subtype, treatment, or grade together with the general difficulties in performing interspecies comparisons, we expected a minimal overlap between significantly regulated pathways in this comparison. However, the analysis revealed pathways that were highly reminiscent of the defining features of MRD described in this manuscript for the mouse models. Specifically, we found a number of overlapping pathways between human datasets and our model systems that pertained to lipid metabolism and redox maintenance (Supplemental Figure 8 and Supplemental Table 4). The presence of lipid metabolic pathways in this analysis supported the finding of dysregulated lipid metabolism as a central hallmark of cells that survive therapeutic intervention. To gain further insight, we plotted the metabolism of lipids and lipopro-
of somatic mutation–driven tumor recurrence via the use of anti-
oxidants further supports the causal role of an unchecked lipid
metabolism in driving tumor recurrence.

Our results support that these characteristics would accel-
erate somatic mutation–driven tumor recurrences and that this
effect is strongly potentiated in a hormone-responsive organ.

Our demonstration that mifepristone successfully delayed tumor
recurrence highlights the possibility of a correlation between hor-
mone-driven proliferation and tumor recurrence. Indeed, one of
the major independent risk factors for local tumor recurrence in
women who have received breast-conserving therapy is “young”
age (premenopausal [<50]; refs. 38, 39). Studies have also high-
lighted a strong association between progesterone-containing
hormone replacement therapy (HRT) treatment and tumor recur-
rence. The 3 randomized trials, Hormonal Replacement After
Breast Cancer - Is It Safe (HABITS), Livial Intervention following
Breast Cancer: Efficacy, Recurrence, And Tolerability Endpoints
analyzed without stratification, PPAR signaling was the most statisti-
cally significant deregulated pathway in the residual cancer cells
(30). Notably, aberrant FA ametabolism was detected in MRD across
all the breast cancer intrinsic subtypes, an observation supported by
positive FASN staining of neoadjuvant-treated patient samples.

Alterations in lipid metabolism have previously been shown
to be a hallmark of breast cancer, with increased overexpression
of some key genes correlating with disease progression (35, 36).
Recently, alterations in energy metabolism have also been shown
to be a hallmark of cells that have survived KRASG12D inactivation
in pancreatic cancer (37). However, the mechanism by which
altered metabolism could drive relapse had not been addressed.
In this study, we demonstrate that regressed mammary glands
have higher levels of FA metabolism. Through direct perturba-
tion of FA metabolism using C75 and etomoxir, we established
that dysregulated lipid metabolism drives elevated oxidative
stress and increased DNA adduct formation in MRD. Attenuation
of somatic mutation–driven tumor recurrence via the use of anti-
oxidants further supports the causal role of an unchecked lipid
metabolism in driving tumor recurrence.

Our results support that these characteristics would accel-
erate somatic mutation–driven tumor recurrences and that this
effect is strongly potentiated in a hormone-responsive organ.
Our demonstration that mifepristone successfully delayed tumor
recurrence highlights the possibility of a correlation between hor-
mone-driven proliferation and tumor recurrence. Indeed, one of
the major independent risk factors for local tumor recurrence in
women who have received breast-conserving therapy is “young”
age (premenopausal [<50]; refs. 38, 39). Studies have also high-
lighted a strong association between progesterone-containing
hormone replacement therapy (HRT) treatment and tumor recur-
rence. The 3 randomized trials, Hormonal Replacement After
Breast Cancer - Is It Safe (HABITS), Livial Intervention following
Breast Cancer: Efficacy, Recurrence, And Tolerability Endpoints

Figure 7. Lipid phenotype of neoadjuvant-treated breast cancers. Network plot for all reactome pathways under the term “Metabolism of lipids and lipoproteins,” which are significantly deregulated in at least one of 4 assays: MYC/KRAS, MYC/NEU, GSE32072, or RNA-seq. Strong significance threshold for mouse assays, $P < 0.005$, and human assays, 0.05. Significance threshold for mouse assays, $P < 0.05$, and human assays, $P < 0.1$. Pathway significance is colored by its best $P$ value in the mouse assays.
The Journal of Clinical Investigation

RESEARCH ARTICLE

mice treated with ROS scavenger NAC. This raises the question of whether it would be beneficial to evaluate the inclusion of antioxidants in a preventive setting following surgical and therapeutic intervention. Supplementation of cytotoxic antitumor therapy regimes with antioxidants has been the subject of many studies (45, 46). There are numerous and conflicting reports concerning the effects of inclusion of antioxidants on overall survival or clinical response; however, these studies are largely addressing the potential of antioxidants, such as vitamins, to interfere with cytotoxic therapies that traditionally rely upon oxidative stress mechanisms to inflict damage on existing cancer cells.

(LIBERATE), and Stockholm trials, of HRT treatment in women with a previous history of breast cancer had to be halted due to concerns about the safety of the treatment following early follow-ups (40–42). Although — even in healthy individuals — late onset of menopause, early menses, and HRT are all associated with a risk in developing breast cancer (43, 44), cyclical expansion of the mammary gland (25) could hasten the acquisition of secondary mutations that drive relapse in breast cancer survivors harboring a mutation-permissive metabolism.

Although not as dramatic as the effect seen with mifepristone, we did see a significant attenuation of tumor recurrence in Figure 8. Postneoadjuvant–treatment human breast cancer samples display elevated FASN and 8-OHdG levels. (A) IHC of healthy mammary tissue and matched preneoadjuvant- and postneoadjuvant-treatment human breast cancer samples for FASN. The images, showing enhanced staining in the tumor samples, are representative for (n = 11) luminal, (n = 10) HER2 3+, and (n = 9) triple negative patient samples for each subtype. HER2 3+, treatment regimen Herceptin + combined hormone therapy (CHT); luminal, aromatase inhibitor; triple negative, CHT. Samples from patients, which were classified as responsive to the neoadjuvant therapy, were chosen for analysis. Scale bar: 50 μm. (B) Immunofluorescence staining of preneoadjuvant- and postneoadjuvant-treatment human breast cancer samples; FASN (cyan), 8OHdG (red), DAPI (gray). The images are representative of (n = 10) patient samples for each subtype. HER2 3+, treatment regimen herceptin + CHT; luminal, aromatase inhibitor; triple negative, CHT. Samples from patients, which were classified as responsive to the neoadjuvant therapy, were chosen for analysis.
In this study, antioxidants were administered as an adjuvant therapy after initial therapeutic intervention. Very few studies have focused on evaluating the influence of vitamin supplementation on long-term outcomes among breast cancer patients. Interestingly, 2 independent prospective cohort studies reported that increased dietary supplementation of vitamins C and E, during the period following cancer diagnosis, confers a protective effect in regard to tumor recurrence and overall survival in breast cancer patients (47, 48). This supports our observations that the use of antioxidants in an adjuvant setting can bestow a survival advantage. The factors governing the efficacy of vitamin supplementation, including effective serum levels and interaction with therapy, is likely to be very complex. However, considering the potential for benefits, it is one that deserves further attention.

Here, we present an approach that combines complementary in vivo and ex vivo systems for characterization of the substrate of breast cancer recurrence. We report a differential energy metabolism, which is active in at least a subpopulation of the surviving cells, and show that these cells have the capability acquiring de novo somatic mutations after oncogene inactivation. It is apparent from our combined computational and cellular approaches that increased lipid metabolism is a metabolic hallmark of cells surviving therapeutic treatment that transcends the etiological differences among human breast tumor subtypes. The commonality of this hallmark strongly suggests that altered energy metabolism could be an Achilles heel for interfering with cancer progression toward relapse and is an attractive subject for future mechanistic and clinical studies.

Methods
Supplemental Methods are available online with this article.

Animals. All the mice were bred and maintained in the EMBL Mouse Biology Unit, Monterotondo, in accordance with Italian legislation and under license from the Italian Health Ministry. Mice were housed under barrier conditions with 12-hour light/12-hour dark cycles. We utilized the following mouse strains: TetO-cMYC, TetO-KrasG12D, MMTV-rtTA as described in ref. 5 and TetO-Neu, MMTV-rtTA as described in Ref. 6.

Tristransgenic TetO-cMYC/TetO-Neu/MMTV-rtTA and TetO-cMYC/TetO-KrasG12D/MMTV-rtTA and bitransgenic TetO-Neu/MMTV-rtTA, TetO-cMYC/TetO-KrasG12D, and TetO-cMYC/TetO-Neu (TT+) control mice were generated, and tumors were induced through the activation of transgene expression, which was achieved by administration of a doxycycline supplemented diet (625 mg/kg doxycycline; Mucedola). Control mice (TT+) were placed on doxycycline, along with experimental animals at 8–10 weeks of age for 30 days; they were then taken off and placed on a normal diet.

Data deposition. Datasets generated as part of this study were deposited at ArrayExpress with the following accession numbers: E-MTAB-3038, E-MTAB-3039, and E-MTAB-4632. Please refer to Supplemental Methods.

Statistics. Graph Pad Prism, version 7.1 (GraphPad Software) was used for generating graphs and preforming statistical tests. This study has employed the use of Student t tests for determining significance between related comparisons; for multiple comparisons, one-way ANOVA was followed by Dunnett’s or Sidak multiple comparison tests. Log-rank Mantel Cox tests were utilized for analyzing significance in relapse-free survival. P values of less than 0.05 were considered statistically significant. Data presented in figure legends is represented as mean ± SEM unless otherwise stated; statistical tests utilized are reported in the figure legends, along with the associated P values.

Study approval. Regarding neoadjuvant-treated patient samples for RNA-seq, the study entitled “Ermittlung neuer Zielproteine für kombinatorische Therapien bei Brustkrebs-Patientinnen sowie die Entwicklung prognostischer und prädiktiver Markerprofile” with the study number S-039-2008 was approved by the Ethical Committee of the Medical Faculty in Heidelberg.

Regarding human breast samples for IHC analysis, the patients were not selected for a clinical trial specifically. All patients came from clinical practice, prospectively entered the European Institute of Oncology breast cancer database, and gave an informed consent for using their clinico-pathological data and samples for research purposes at the time of admission to the hospital. The procedures were approved by the IEO Review Board.

Author contributions
KMH and MJ designed the experiments. KMH carried out the experiments. JS cultured cells and isolated RNA for affymetrix analysis. VM and BK performed comparison with GSE32072. BK analyzed the RNA-seq data. VM and KRP ran reporter metabolite analysis. KR and EK performed the GC-MS analysis. KR, AA, and MG performed experiments and stainings. TJG and KRP supervised the computational work. BB and AS provided human samples for RNA-seq. GP and NR provided human samples for histology. KMH and MJ wrote the manuscript. MJ and RS supervised the work.

Acknowledgments
We thank Jelena Pistolic for technical assistance in preparation and hybridization of the samples to the affymetrix platforms; Federico Villa for assistance with tissue culture and sample preparation; Cora Chadwick and Daniel Bilbao for expert assistance with FACS sorting; Giuseppe Chiapparelli for mouse husbandry; Prasad Phapale and the Metabolomics Core Facility for expert assistance; Grischa Tödt for suggestions toward probe reannotation of the array datasets; and Donal O’Carroll, Darren Gilmour, and Jan Ellenberg for critical readings of the manuscript. This study was technically supported by EMBL Monterotondo Microscopy Facility and the Laboratory for Animal Resources. KMH was supported by the EMBL Interdisciplinary Postdoc Program under Marie Curie COFUND Actions. Work in RS’s laboratory is supported by the European Research Council under the European Union’s Seventh Framework Programme (FP7-2007-2012)/ERC grant agreement number ERC-281614, Marie Curie PCIG09-GA-2011-293745, and the Howard Hughes Medical Institute. Work in MJ’s laboratory is supported by Marie Curie PCIG-GA-2011-294121, 3DBreastCancer.

Address correspondence to: Martin Jechlinger, EMBL Heidelberg, Cell Biology and Biophysics unit, Meyerhofstraße 1, 69117 Heidelberg, Germany. Phone: 49.6221.3878401; E-mail: martin.jechlinger@embl.de.

JS’s present address is: University of Basel Medical Faculty, Basel, Switzerland.